Anti-DR5/CD262 Antibody, clone 1B19 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1B19 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects Death receptor 5 (DR5/CD262). It targets an epitope within 16 amino acids from the internal region.

KLH-conjugated linear peptide corresponding to 16 amino acids from the internal region of human Death receptor 5 (DR5/CD262).

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected DR5/CD262 in HeLa cell lysate.

Tested applications

Flow Cytometry Analysis: 1 μg from a representative lot detected DR5/CD262 in one million A431 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected DR5/CD262 in human kidney tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound DR5 with a KD of 6.2 x 10-6 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected DR5/CD262 in A431 and NIH 3T3 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Tumor necrosis factor receptor superfamily member 10B (UniProt: O14763; also known as Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2, CD262) is encoded by the TNFRSF10B (also known as DR5, KILLER, TRAILR2, TRICK2, ZTNFR9) gene (Gene ID: 8795) in human. DR5/CD262 is a single-pass type I membrane protein that is synthesized with a signal peptide (aa 1-55), which is subsequently cleaved off to generate the mature form that contains an extracellular domain (aa 56-210), a transmembrane domain (aa 211-231), and a cytoplasmic domain (aa 232-440). It is a pro-apoptotic member of the tumor necrosis factor receptor superfamily that is constitutively expressed in various tissue types and forms auto-inhibited dimers in its resting state. It is widely expressed in adult and fetal tissues and its higher expression is observed in heart, peripheral lymphocytes, liver, pancreas, spleen, placenta, and throughout the intestinal tract. High expression of DR5/CD262 is also reported in various cancer cell lines. In its resting state, it is a monomeric protein that serves as a receptor for TRAIL (TNFSF10) and mediates apoptotic cell death. In its canonical mode of activation, binding of its ligand TRAIL assembles it into higher-order oligomers that forms intracellular scaffolds in which its cytosolic death domains recruit the adaptor protein FADD and pro-caspase 8 into the death-inducing signaling complex (DISC). Subsequently, pro-caspase 8 undergoes auto-proteolysis to form active initiator caspase 8. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Lam, M., et al. (2020). eLife. 9; e52291; Sun, SY., (2011). Mol. Cell Pharmacol. 3(1); 31-34).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.